Patents by Inventor Daniel Kuzmich

Daniel Kuzmich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclohexanol ethers as mediterranean fruit fly attractants
    Patent number: 10343974
    Abstract: Disclosed are novel cyclohexanol ethers of Formula (I) useful as Mediterranean fruit fly, Ceratitas capitata, attractants: wherein R1 is C1-5 alkyl optionally substituted with 0-3 halogens, and R2 is C1-3 alkyl. Also disclosed are methods of preparation, methods of formulation, and methods of use.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: July 9, 2019
    Assignee: The United States of America, as represented by The Secretary of America
    Inventors: Daniel Kuzmich, Spencer S. Walse
  • Diastereoselective synthesis of (±)-epianastrephin, (±)-anastrephin and analogs thereof
    Patent number: 10011580
    Abstract: A process for the synthesis of trans-fused ?-lactones having Formula (IV) from substituted cyclic ketones having Formula (I).
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: July 3, 2018
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Spencer S. Walse, Daniel Kuzmich
  • Diastereoselective Synthesis of (±)-Epianastrephin, (±)-Anastrephin and Analogs Thereof
    Publication number: 20170305874
    Abstract: A process for the synthesis of trans-fused ?-lactones having Formula (IV) from substituted cyclic ketones having Formula (I).
    Type: Application
    Filed: April 20, 2017
    Publication date: October 26, 2017
    Inventors: Spencer S. Walse, Daniel Kuzmich
  • Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists
    Patent number: 9056858
    Abstract: Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1, X and G are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: June 16, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas Cook, Daniel Kuzmich, Can Mao, Hossein Razavi
  • Heterocyclic compounds as CCR1 receptor antagonists
    Patent number: 8927550
    Abstract: Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: January 6, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas Cook, Daniel Kuzmich
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
    Patent number: 8741897
    Abstract: Compounds of Formula (IA), (IB), (IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: June 3, 2014
    Assignee: Boehringer Ingelheim Pharmaceuticals Inc.
    Inventors: Younes Bekkali, Rajashekhar Betageri, Michel J. Emmanuel, Abdelhakim Hammach, Christian Hanke Justus Joachim Harcken, Thomas Martin Kirrane, Jr., Daniel Kuzmich, Thomas Wai-Ho Lee, Pingrong Liu, Usha R. Patel, John Robert Proudfoot, Hossein Razavi, Doris Riether, Hidenori Takahashi, David S. Thomson, Ji Wang, Renee Zindell
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
    Patent number: 8658637
    Abstract: Compounds of Formula (IA) wherein R1, R2, R3, A, B, C, D, E, G, X, Y, and Z are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: February 25, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Daniel Kuzmich, Darren DiSalvo, Hossein Razavi, Michael Jason Burke
  • Pyrazolopiperidine compounds as CCR1 receptor antagonists
    Patent number: 8546442
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: October 1, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rajashekhar Betageri, Brian Nicholas Cook, Darren DiSalvo, Christian Harcken, Daniel Kuzmich, Pingrong Liu, John Lord, Can Mao, Hossein Razavi
  • Pyridinyl compounds useful as intermediates
    Patent number: 8338610
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: December 25, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Daniel Kuzmich, Pingrong Liu, Hossein Razavi
  • Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists
    Publication number: 20120322790
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
    Type: Application
    Filed: December 16, 2011
    Publication date: December 20, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rajashekhar BETAGERI, Brian Nicholas COOK, Darren DiSALVO, Christian HARCKEN, Daniel KUZMICH, Pingrong LIU, John LORD, Can MAO, Hossein RAZAVI
  • Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists
    Publication number: 20120270870
    Abstract: Diclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1, X and G are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).
    Type: Application
    Filed: October 19, 2010
    Publication date: October 25, 2012
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas Cook, Daniel Kuzmich, Can Mao, Hossein Razavi
  • Heterocyclic Compounds As CCR1 Receptor Antagonists
    Publication number: 20120270879
    Abstract: Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the formula (I).
    Type: Application
    Filed: October 21, 2010
    Publication date: October 25, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Brian Nicholas Cook, Daniel Kuzmich
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
    Patent number: 8268859
    Abstract: Compounds of Formula (I) wherein R1, R2, X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: September 18, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Harcken, Rajashekhar Betageri, Todd Bosanac, Michael Jason Burke, Soojin Kim, Daniel Kuzmich, Thomas Wai-ho Lee, Zhibin Li, Pingrong Liu, John Lord, Hossein Razavi, Jonathan Timothy Reeves, David Thomson
  • Indazole compounds as CCR1 receptor antagonists
    Patent number: 8263597
    Abstract: Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: September 11, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Daniel Kuzmich, Can Mao, Alan David Swinamer, David Smith Thomson
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof
    Patent number: 8212040
    Abstract: Compounds of Formula (IA) wherein R1, R2, R3, R4 and R5 are as defined herein for Formula (IA), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: July 3, 2012
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Rajashehar Betageri, Mario G. Cardozo, Thomas A. Gilmore, Christian Hanke Justus Joachim Harcken, Thomas Martin Kirrane, Daniel Kuzmich, John Robert Proudfoot, Doris Riether, Hidenori Takahashi, David S. Thomson, Ji Wang, Renee M. Zindell, Hossein Razavi
  • Pyridinyl Compounds Useful As Intermediates
    Publication number: 20120136158
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.
    Type: Application
    Filed: February 8, 2012
    Publication date: May 31, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Brian Nicholas COOK, Darren DiSALVO, Daniel Robert FANDRICK, Christian HARCKEN, Daniel KUZMICH, Thomas Wai-Ho LEE, Pingrong LIU, John LORD, Can MAO, Jochen NEU, Brian Christopher RAUDENBUSH, Hossein RAZAVI, Jonathan Timothy REEVES, Jinhua J. SONG, Alan David SWINAMER, Zhulin TAN
  • Azaindazole compounds as CCR1 receptor antagonists
    Patent number: 8163918
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: April 24, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Daniel Kuzmich, John Lord, Can Mao
  • Azaindazole Compounds As CCR1 Receptor Antagonists
    Publication number: 20120035370
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas COOK, Darren DiSALVO, Daniel Robert FANDRICK, Christian HARCKEN, Daniel KUZMICH, Thomas Wai-Ho LEE, Pingrong LIU, John LORD, Can MAO, Jochen NEU, Brian Christopher RAUDENBUSH, Hossein RAZAVI, Jonathan Timothy REEVES, Jinhua J. SONG, Alan David SWINAMER, Zhulin TAN
  • Indazole Compounds As CCR1 Receptor Antagonists
    Publication number: 20110294808
    Abstract: Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: July 18, 2011
    Publication date: December 1, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Daniel KUZMICH, Can MAO, Alan David SWINAMER, David Smith THOMSON
  • Azaindazole compounds as CCR1 receptor antagonists
    Patent number: 8063065
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: November 22, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas Cook, Darren Di Salvo, Christian Harcken, Daniel Kuzmich, Thomas Wai-Ho Lee, Pingrong Liu, John Lord, Can Mao, Jochen Neu, Brian Christopher Raudenbush, Hossein Razavi, Alan David Swinamer